RT Journal Article
SR Electronic
A1 Rizzo, Toni
T1 Sustained Virologic Response of 91% in Patients Infected with HCV Treated with DCV-TRIO
JF MD Conference Express
YR 2014
FD SAGE Publications
VO 14
IS 48
SP 15
OP 16
DO 10.1177/155989771448009
UL http://mdc.sagepub.com/content/14/48/15.abstract
AB Daclatasvir is a pangenotypic (genotypes [GT] 1–6 in vitro and GT 1–4 in clinical trials) NS5A inhibitor with a low potential for drug-drug interactions. It is approved in Europe and Japan, and it is under regulatory review in the United States. The aim of the phase 3 UNITY-1 trial [NCT01979939] was to evaluate this all-oral, ribavirin-free combination in noncirrhotic treatment-naïve and treatment-experienced patients with hepatitis C virus (HCV) genotype (GT) 1 infection.